On second thought, lenalidomide does improve DLBCL outcomesJuly 15, 2019DLBCLLymphoma & Plasma Cell Disorders
SC daratumumab deemed feasible for every multiple myeloma patientJuly 11, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
CNS-directed therapy appears more effective for synDLBCLJuly 9, 2019Lymphoma & Plasma Cell DisordersDLBCL
Daratumumab wins new indication for newly diagnosed myeloma patientsJune 28, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Cell count ratios appear to predict thromboembolism in lymphomaJune 25, 2019ThrombosisLymphoma & Plasma Cell DisordersHodgkin Lymphoma
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomasJune 21, 2019Aggressive LymphomasLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
5F9 plus rituximab take a bite out of drug-resistant NHLJune 18, 2019Aggressive LymphomasLymphoma & Plasma Cell Disorders
Obinutuzumab provides strong early responses in untreated MCLJune 17, 2019Lymphoma & Plasma Cell Disorders
‘Encouraging’ responses seen with durvalumab plus R-CHOP in DLBCLJune 17, 2019Lymphoma & Plasma Cell DisordersAggressive Lymphomas
Triplet offers longest PFS yet seen in relapsed/refractory myelomaJune 12, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Four-drug combo bests triplet in newly diagnosed myelomaJune 12, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Inhibitor produces high response rate in relapsed/refractory FLJune 11, 2019Lymphoma & Plasma Cell Disorders
